Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal positive aspects: expansion plans, optimistic guidance on reaching cash breakeven, and strong market momentum for PAPZIMEOS. Despite some risks like cold chain logistics and regulatory compliance, the company’s financial health is stable with $123.6 million in cash and investments. The Q&A reassures on patient reimbursement and market adoption. The stock price is likely to react positively in the short-term, driven by optimistic guidance and market expansion strategies.
Key Financial Performance
Cash, Cash Equivalents, and Investments $123.6 million as of September 30, 2025, following the drawdown of the first tranche of the credit facility. This balance, along with projected revenues from PAPZIMEOS, is expected to fund operations to cash breakeven.
Inventory Approximately $3 million as of September 30, 2025, representing manufacturing costs incurred after PAPZIMEOS approval. Costs incurred prior to approval were expensed as R&D expenses.
SG&A Costs Increased by approximately $14 million in Q3 2025 compared to the same quarter in the prior year. The increase was primarily due to commercialization spending for PAPZIMEOS launch and additional employee-related costs, including share-based awards.
Net Loss Attributable to Common Shareholders $1.06 per share for Q3 2025, which includes $0.95 per share from two non-cash items: a change in warrant liability and a deemed dividend related to preferred share conversion. These items are not expected to recur in future periods.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PAPZIMEOS Approval: PAPZIMEOS was approved in August 2025 as the first and only treatment for adults with recurrent respiratory papillomatosis (RRP). It demonstrated unmatched efficacy, with 51% of patients achieving complete response and 86% reducing surgical burden. The treatment is subcutaneous, easy to administer, and has a favorable safety profile.
Pediatric Clinical Trial: Precigen is working towards initiating a clinical trial for PAPZIMEOS in the pediatric RRP population.
Geographic Expansion: Precigen has submitted a marketing authorization application for PAPZIMEOS with the European Medicines Agency (EMA).
U.S. Market Penetration: PAPZIMEOS has been shipped to U.S. prescribers, with 90% of target institutions engaged and over 100 patients registered for treatment. Payer coverage includes over 80 million lives, Medicare, and Medicaid.
Manufacturing Operations: Precigen operates a dedicated in-house cGMP facility for PAPZIMEOS production, ensuring control over manufacturing and supply to meet current and future demand. The facility passed FDA pre-approval inspection and has validated logistics for distribution.
Financial Position: Precigen has $123.6 million in cash and investments, sufficient to fund operations to cash breakeven, including PAPZIMEOS launch costs and pipeline development.
Transition to Commercial State: The approval of PAPZIMEOS marks Precigen's transition to a commercial company, with significant investments in infrastructure, including a new ERP system, to support this shift.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Compliance: The company has made significant investments in cGMP manufacturing and successfully passed FDA pre-approval inspections. However, maintaining compliance with regulatory standards and managing post-approval requirements could pose challenges.
Cold Chain Logistics: PAPZIMEOS requires a cold chain for distribution. While the company has validated logistics and most target centers are equipped to handle frozen products, any disruptions in the cold chain could impact product adoption and distribution.
Financial Sustainability: The company is relying on projected revenues from PAPZIMEOS to achieve cash breakeven. Any shortfall in revenue or unexpected costs could strain financial resources.
Market Penetration: The company is working to establish PAPZIMEOS as the standard of care for RRP. However, achieving widespread adoption and overcoming potential competition could be challenging.
Manufacturing Capacity: The company operates an in-house cGMP facility for PAPZIMEOS production. Any issues in scaling up manufacturing to meet demand could impact supply.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
PAPZIMEOS Pediatric RRP Clinical Trial: The company is working towards the initiation of a clinical trial for PAPZIMEOS targeting the pediatric RRP population.
Geographic Expansion of PAPZIMEOS: Precigen has submitted a marketing authorization application with the EMA to expand PAPZIMEOS availability geographically.
Projected Revenues and Financial Guidance: The company expects its cash and investment balance, combined with projected revenues from PAPZIMEOS, to fund operations to cash breakeven, including launch costs and pipeline development.
Gross-to-Net Revenue Adjustment: The gross-to-net revenue adjustment is anticipated to be in the high teens to low 20% range, consistent with industry peers.
Market Momentum and Q1 2026 Outlook: The company expects to build on the current market momentum of PAPZIMEOS throughout Q4 2025 and into Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Have any patients received reimbursement approvals or been dosed with PAPZIMEOS?
A:Patients are being scheduled for treatment, and payer coverage is progressing. Specific details about patients being dosed will be shared in Q4 earnings.
Q:How should we think about the cadence of pull-through from patients registered in the hub to getting a reimbursed drug?
A:Patients are ready for benefit verification and prior authorization. Pull-through will vary by institution but is expected to pick up pace in Q4.
Q:Do you expect the majority of patients in the hub to receive the drug?
A:Yes, the expectation is that the majority of patients in the hub will receive the drug.
Q:What assumptions are being made regarding the statement that the company is funded to cash flow breakeven?
A:The company is not guiding on revenue but expects to reach cash flow breakeven by the end of 2026.
Q:How long will the bolus of patients last given the pent-up demand and reimbursement hurdles?
A:The bolus of patients is expected to last for a while, supported by the broad label and the identified 27,000 adult patients in the system.
Q:How should we think about subsequent cycles of therapy and payer allowance for redosing beyond the first 4 doses?
A:Redosing is at the physician's discretion and supported by safety, efficacy, and durability data. Payers are expected to support redosing based on the drug's durability.
Q:How is PAPZIMEOS revenue recorded on financial statements?
A:Revenue is recognized when the title transfers to the specialty pharmacy, IDN, or community hospital, not when the injection occurs.
Q:What is the size and trajectory of the registered patient population in the hub?
A:The hub is recruiting patients rapidly, and the majority of registered patients are expected to receive PAPZIMEOS. There is a high sense of urgency among physicians to expedite access.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about patients being dosed with PAPZIMEOS and did not guide on revenue assumptions for cash flow breakeven.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Commercial
Chief Officer
HCPs
IDNs
PAPZIMEOS approval
PAPZIMEOS drug
PAPZIMEOS standard
PAPZIMEOS treatment
RRP Foundation
RRP population
achievement
adult RRP
bar
burden
cGMP
community practice
competitor
date
device
drug product
efficacy endpoint
house
institution
label adult
line expectation
momentum
patient response
result population
safety profile
service
space
speed
standard care
study efficacy
summary
support
treatment PAPZIMEOS
treatment adult
trial RRP
week
PGEN Transcript
Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Positive5-13
The company anticipates a significant revenue increase due to strong adoption of PAPZIMEOS, supported by a permanent J-code, and geographic expansion plans. Despite regulatory and strategic risks, the optimistic guidance and expected cash flow breakeven by 2026 indicate a positive outlook. The lack of financial details in the call is offset by the promising strategic initiatives and market trends.
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Positive3-25
The earnings call highlights strong financial performance with a 149% revenue increase, despite a net loss due to non-recurring items. The Q&A reveals positive progress in patient conversion and treatment completion, and management's optimism about the European market. The J-code is expected to enhance patient processing, and the revenue guidance is clear. While there is uncertainty about European approval timing, the overall sentiment is positive, driven by strong revenue growth and operational improvements.
Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
PGEN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
